Michael Greenberg - Allergan Plc Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
Dr. Michael E. Greenberg, Ph.D. is Director of the Company. Dr. Greenberg was Harvard Universitys Nathan Marsh Pusey Professor of Neurobiology since 2008. He was a CoLeader of Harvard Medical Schools Allen Discovery Center for Human Brain Evolution since 2017 and Chair of the Department of Neurobiology since 2008. He was also Founding Director of the F.M. Kirby Neurobiology Center, Childrens Hospital Boston, where he continues to serve as director. Prior to that he was a Professor in the Department of Microbiology Molecular Genetics at Harvard Medical School
Age: 63  Director Since 2018  Ph.D    
862 261 7000  http://www.allergan.com
Greenberg earned his Doctor of Philosophy from Rockefeller University and a Bachelor of Arts degree from Wesleyan University. He completed his postdoctoral fellowship at New York University Medical Center. He currently serves on the Scientific Advisory Board of Decibel Therapeutics.

Michael Greenberg Latest Insider Activity

Michael Greenberg over two weeks ago via Macroaxis 
Skechers U exotic insider transaction detected
Michael Greenberg over three weeks ago via Macroaxis 
Skechers U exotic insider transaction detected
Michael Greenberg over a month ago via Macroaxis 
Skechers U exotic insider transaction detected
Michael Greenberg over a month ago via Macroaxis 
Sale by Michael Greenberg of 200 shares of Skechers U

Allergan Plc Management Efficiency

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) % meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has Current Ratio of 0.98 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Shantanu NarayenPfizer Inc
Dan LittmanPfizer Inc
Marc TessierLavigneRegeneron Pharmaceuticals
Geoffrey ParkerPerrigo Company Plc
Willie ReedZoetis Inc
Hans HaslerDr Reddys Laboratories
Anthony ColesRegeneron Pharmaceuticals
Dennis AusielloPfizer Inc
Paul BisaroZoetis Inc
Alfred GilmanRegeneron Pharmaceuticals
Jeffrey SmithPerrigo Company Plc
Ellen HoffingPerrigo Company Plc
Michael JandernoaPerrigo Company Plc
Sanjay KhoslaZoetis Inc
Frank DAmelioZoetis Inc
Joseph GoldsteinRegeneron Pharmaceuticals
Theodore SamuelsPerrigo Company Plc
Gary CohenPerrigo Company Plc
Don CornwellPfizer Inc
Louise ParentZoetis Inc
Donal OConnorPerrigo Company Plc

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Stock Performance Indicators

Did you try this?

Run Earnings Calls Now


Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Vertex Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page